Its role Owner
Dexcom, Inc. is a U.S. medical device company that develops, manufactures, and markets continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, California, the company operates globally and is listed on Nasdaq (DXCM).
Dexcom’s CGM technology combines enzyme-based electrochemical sensing with biocompatible polymer membranes, medical-grade adhesives, and miniaturized electronics to measure interstitial glucose in real time. Its operations span sensor chemistry R&D, materials engineering, sterile high-volume production of single-use sensor components, and software for data visualization and connectivity, including interoperability with insulin delivery systems and digital health platforms. The company serves patients, clinicians, and health systems and operates under regulated medical device frameworks (such as FDA and CE). Dexcom’s work sits at the intersection of biosensor chemistry, advanced materials, and precision manufacturing, linking it to the broader life-sciences and specialty chemicals value chain.
chemXplore tracks 1 project involving Dexcom, of which one is active.
The new facility in Galway will create up to 1,000 high-skilled jobs, supported by the Irish Government, and focus on automated, green technologies for continuous glucose monitoring.
active all projects
